2.52
0.07 (2.86%)
| Penutupan Terdahulu | 2.45 |
| Buka | 2.45 |
| Jumlah Dagangan | 156,053 |
| Purata Dagangan (3B) | 396,554 |
| Modal Pasaran | 129,171,136 |
| Harga / Buku (P/B) | 6.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| EPS Cair (TTM) | -0.960 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.67% |
| Nisbah Semasa (MRQ) | 3.00 |
| Aliran Tunai Operasi (OCF TTM) | -15.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -15.19 M |
| Pulangan Atas Aset (ROA TTM) | -90.68% |
| Pulangan Atas Ekuiti (ROE TTM) | -332.67% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | TuHURA Biosciences, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -4.0 |
| Purata | -0.75 |
|
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 41.96% |
| % Dimiliki oleh Institusi | 8.43% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Suncoast Equity Management | 30 Sep 2025 | 104,409 |
| Sabal Trust Co | 31 Mar 2025 | 39,427 |
| Julat 52 Minggu | ||
| Median | 8.00 (217.46%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Maxim Group | 14 Nov 2025 | 8.00 (217.46%) | Beli | 2.05 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |